FWC
JUNO

First Washington Corp’s Juno Therapeutics, Inc. JUNO Stock Holding History

First Washington Corp’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-65,320
Closed -$1.96M – 78
2016
Q3 		$1.96M Buy
65,320
+25,620
+65% +$797K 1.1% 39
2016
Q2 		$1.53M Buy
39,700
+500
+1% +$20.8K 0.88% 40
2016
Q1 		$1.49M Buy
+39,200
New +$1.37M 0.88% 40

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First Washington Corp's JUNO Position: Q4 2016 in Review

First Washington Corp sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 65,320 shares — an estimated $1.96M sold.

First Washington Corp first reported a position in JUNO in Q1 2016 and held it in 3 quarters. The position peaked at $1.96M in Q3 2016. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

  • First Washington Corp reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • First Washington Corp sold 65,320 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $1.96M.
  • First Washington Corp first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 3 quarters.
  • First Washington Corp's Juno Therapeutics, Inc. position peaked at $1.96M in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on First Washington Corp's 13F filing for Q4 2016, filed 9 Feb 2017.